Pfizer Inc. (PFE)
Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline
Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.
Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcare conference on Monday.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make it a strong candidate for high-yield income portfolios. Insider buying and positive net money flow indicate confidence in the Company's stability and potential for a 20% yield through dividends and covered calls.
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE.
Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on Friday following data from a late-stage study.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine other aspects, especially those often overlooked by dividend investors. JNJ offers better growth, a stronger track record, and also a safer payout.
Is Pfizer Stock Undervalued at Current Prices?
Pfizer (PFE -0.07%) stock investors are curious about the valuation and prospects for the healthcare company.
Should You Buy Pfizer Stock Right Now in 2025?
Pfizer (PFE 0.20%) is an interesting healthcare company with excellent prospects for cash flow growth.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer's PFE stock has risen 5.6% in the past month. This was due to the company's encouraging guidance for 2025 issued in mid-December 2025.
